WO2006064825A1 - Agent therapeutique pour la secheresse oculaire - Google Patents

Agent therapeutique pour la secheresse oculaire Download PDF

Info

Publication number
WO2006064825A1
WO2006064825A1 PCT/JP2005/022913 JP2005022913W WO2006064825A1 WO 2006064825 A1 WO2006064825 A1 WO 2006064825A1 JP 2005022913 W JP2005022913 W JP 2005022913W WO 2006064825 A1 WO2006064825 A1 WO 2006064825A1
Authority
WO
WIPO (PCT)
Prior art keywords
dihydroxy
group
fluorophenyl
dry eye
hydroxy
Prior art date
Application number
PCT/JP2005/022913
Other languages
English (en)
Japanese (ja)
Inventor
Masatsugu Nakamura
Shin-Ichiro Hirai
Keiichi Shibagaki
Original Assignee
Santen Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co., Ltd. filed Critical Santen Pharmaceutical Co., Ltd.
Publication of WO2006064825A1 publication Critical patent/WO2006064825A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Definitions

  • the present invention relates to a therapeutic agent for dry eye comprising a statin compound as an active ingredient.
  • the cornea is a transparent avascular tissue having a diameter of about 1 cm and a thickness of about 1 mm
  • the conjunctiva is a mucous membrane covering the surface of the eyeball behind the cornea edge and the back of the eyelid. It is known that when the cornea and conjunctiva are damaged, visual function is seriously affected. Corneal and conjunctival damage associated with dry eye adversely affects the normal reconstruction of the corneal epithelium and conjunctival epithelium, and as a result, the structure and function of the corneal stroma and corneal endothelium can be impaired.
  • Non-patent document 1 Non-patent document 2
  • statin compounds are known to suppress the biosynthesis of blood cholesterol and are widely used as therapeutic agents for hyperlipidemia and the like.
  • Patent Document 1 describes that statins such as atorvastatin, lovastatin, pravastatin, flupastatin, cerivastatin, and simpastatin are useful as immunomodulators, immune inhibitors, and anti-inflammatory agents.
  • Patent Document 2 describes that statin compounds such as cerivastatin, atorvastatin, sympastatin, and pravastatin are useful as therapeutic agents for TNF_a related diseases such as inflammatory diseases and cardiovascular diseases.
  • statin compounds have no reports on the pharmacological effects of statin compounds on keratoconjunctival diseases such as dry eye.
  • Patent Document 1 Japanese Translation of Special Publication 2004-512278
  • Patent Document 2 Japanese Patent Laid-Open No. 2001-294526
  • Non-Patent Document 1 Eyesight, 46, 738-743 (1992)
  • Non-Patent Document 2 Ophthalmic Surgery, 5, 719-727 (1992)
  • statin compounds were conducted intensive research in order to search for new pharmaceutical uses of statin compounds.
  • a corneal disorder healing efficacy test using a rat dry eye model (+)-(IS, 3R, 7S, 8S, 8aR) -3, 7 Dimethinole 1, 2, 3, 7, 8, 8a Hexahydro 8-
  • a therapeutic agent for dry eye or a disease associated with dry eye comprising a compound represented by the following general formula (1) or a salt thereof as an active ingredient,
  • A represents a lower alkylene group or a lower alkenylene group
  • Ring X represents a non-aromatic ring or a nitrogen-containing aromatic heterocycle
  • R 1 represents a hydrogen atom or a lower alkyl group
  • R 2 represents a hydroxy group
  • R 1 and R 2 may be condensed to form a rataton ring
  • R 3 represents a hydrogen atom or a lower alkyl group
  • R 4 is an optionally substituted lower alkyl group, cycloalkyl group, optionally substituted aryl group, hydroxy group or ester thereof, lower alkoxy group, carboxyl group or amide thereof, or lower alkyl An amino group or an amide thereof; m represents an integer of 0 to 4, and when m is 2 or more, each R 4 may be the same or different. )
  • R 5 and R 6 are the same or different and each represents a hydrogen atom, a hydroxy group, a lower alkoxy group or a lower alkyl group;
  • R 7 represents a hydroxy group or an ester thereof
  • R 8 and R 11 are the same or different and each represents a hydrogen atom, a lower alkyl group or an aryl group which may have a substituent;
  • R 9 and R 1Q are the same or different and each represents an optionally substituted aryl group, carboxy group or amide thereof;
  • R 12 represents a hydrogen atom or a lower alkyl group
  • R represents a hydrogen atom or a lower alkyl group
  • R 14 represents a hydrogen atom or a lower alkyl group which may have a substituent
  • R 15 represents an aryl group which may have a substituent
  • R 16 and R 18 are the same or different and each represents a hydrogen atom, a lower alkyl group or an aryl group which may have a substituent;
  • R 17 represents a lower alkylamino group or an amide thereof
  • R 19 represents a hydrogen atom or a lower alkyl group
  • R 2Q represents an aryl group which may have a substituent
  • R 21 represents an aryl group which may have a substituent
  • R 22 represents a cycloalkyl group before [1] or [2], or dry eye or a therapeutic agent for a disease associated with dry eye,
  • the “lower alkylene group” refers to a linear or branched alkylene group having 1 to 8 carbon atoms.
  • methylene, ethylene, trimethylene, tetramethylene, pentamethylene, hexamethylene, heptamethylene, otatamethylene, methylmethylene, ethylmethylene group and the like can be mentioned.
  • lower alkenylene group refers to a linear or branched alkenylene group having 2 to 8 carbon atoms.
  • Non-aromatic ring means a monocyclic or bicyclic non-cyclic ring having 6 to 10 carbon atoms, and may contain:! To 2 double bonds in the ring.
  • An aromatic hydrocarbon ring is shown.
  • Nitrogen-containing aromatic heterocycle means:! ⁇ A single 4 to 9 carbon atom having 2 nitrogen atoms A cyclic or bicyclic aromatic heterocycle is shown.
  • Examples include pyrrole, pyrazole, imidazole, pyridine, pyridazine, pyrimidine, pyrazine, quinoline, isoquinoline, phthalazine, cinnoline, quinazoline, quinoxaline, indole, isoindole, indazole, benzoimidazole ring, preferably pyrrole, Examples include pyridine, quinoline and indole rings.
  • the "lower alkyl group” refers to a straight or branched alkyl group having from 6 to 6 carbon atoms. Examples thereof include methinole, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, se c-butinole, tert-butinole, n_pentinole, isopentinole, neopentinole, n_hexinole, isohexenole group and the like.
  • the substituent of the "lower alkyl group optionally having substituent (s)" represents one or two groups selected from a hydroxy group and a lower alkoxy group.
  • cycloalkyl group refers to a cycloalkyl having 3 to 8 carbon atoms.
  • cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclooctyl group and the like can be mentioned.
  • the "lower alkoxy group” refers to straight-chain or branched alkoxy having 1 to 6 carbon atoms. For example, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy, n-pentyloxy, n xyloxy groups and the like are shown.
  • aryl group refers to a monocyclic or bicyclic aromatic hydrocarbon having 6 to 10 carbon atoms.
  • a phenyl, a naphthyl group, etc. are mentioned,
  • substituent of “optionally substituted aryl group” is 1 or 2 groups selected from a halogen atom and an alkyl group.
  • Halogen atom refers to a fluorine, chlorine, bromine or iodine atom.
  • Ester of hydroxy group refers to an ester composed of a hydroxy group and an aliphatic carboxylic acid.
  • the aliphatic carboxylic acid refers to a straight-chain or branched monocarboxylic acid having 1 to 7 carbon atoms. Specific examples thereof include formic acid, acetic acid, propionic acid, butyric acid, valeric acid, 2-methylbutane. Examples include acid and 2,2_dimethylbutanoic acid.
  • the “carboxy group amide” refers to an amide having a carboxy group and ammonia, a primary or secondary amine, and the like.
  • the amine may be a lower alkylamine or an arylamine, and specific examples of the lower alkylamine include methylamine, ethylamine, ethylmethylamine, dimethylamine, jetylamine, dihexylamine and the like, and specific examples of the arylamine are ananiline, naphthylamine. Etc.
  • lower anolenoquinamino group refers to a mono- or dialkylamino group in which a hydrogen atom of an amino group is substituted 1 or 2 with the lower alkyl group.
  • Specific examples of the monoalkylamino group include methinoreamino, ethenoreamino, and ethylmethylamino.
  • Specific examples of the dialkylamino group include dimethylenoamino, dimethylamino-containing dihexylamino, and the like.
  • the "amide of a lower alkylamino group” refers to a sulfonic acid amide composed of a lower alkylamino group and an aliphatic sulfonic acid.
  • the aliphatic sulfonic acid refers to a linear or branched monosulfonic acid having from 6 to 6 carbon atoms. Specific examples include methanesulfonic acid, ethanesulfonic acid, hexanesulfonic acid, 2-butanesulfonic acid and the like.
  • Lataton ring refers to a 6-membered ⁇ -latathon ring.
  • the “salt” in the present compound is not particularly limited as long as it is a pharmaceutically acceptable salt.
  • an inorganic acid such as hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid, sulfuric acid, phosphoric acid, etc.
  • Salt acetic acid, fumaric acid, maleic acid, succinic acid, citrate, tartaric acid, adipic acid, darconic acid, darcoheptic acid, glucuronic acid, terephthalic acid, methanesulfonic acid, lactic acid, hippuric acid, 1, 2 —Ethane disulfonic acid, isethionic acid, ratatobionic acid, oleic acid, pamoic acid, polygalatathuronic acid, stearic acid, tannic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, ⁇ -tonoleenesulfonic acid, lauryl sulfate, methyl sulfate , Salts with organic acids such as naphthalene sulfonic acid and sulfosalicylic acid, quaternary ammonium salts with methyl bromide, methyl iodide, bromine ion, chlorine ion Salt
  • the present compound may be in the form of a hydrate or a solvate.
  • Preferable specific examples of the present compound include, for example, (+)-one (IS, 3R, 7S, 8S, 8aR) — 3, 7 Dimethinole 1, 2, 3, 7, 8, 8a Hexahydro 8— [2 — [(2R, 4R) — 4-hydroxy-6-oxotetrahydro-1 2H pyran-1-yl] ethyl] 1 naphthyl 2, 2-dimethylbutanoate (sympastatin), (+) — (3R, 5R) — 3, 5-Dihydroxy 1 7 — [(IS, 2S, 6S, 8S, 8aR) -1, 2, 6, 7, 8, 8a Hexahydro 1-6 Hydroxy 1 2-Methyl-8— [(2S) — 2-Methylbutyryloxy] 1 naphthyl] heptanoic acid (Pura / statin), (+) (IS, 3R, 7S, 8S, 8aR) -3, 7 Dimethinole 1,
  • the disease associated with dry eye is not particularly limited as long as it is a disease associated with dry eye, such as corneal ulcer, punctate superficial keratopathy, corneal epithelial defect, conjunctival epithelial defect and the like.
  • the therapeutic agent for dry eye or a disease associated with dry eye according to the present invention can be administered either orally or parenterally.
  • Examples of the dosage form include eye drops, eye ointments, injections, tablets, capsules, granules, powders and the like, and eye drops are particularly preferable. These can be formulated using widely used techniques.
  • eye drops include isotonic agents such as sodium chloride and concentrated glycerin, buffering agents such as sodium phosphate and sodium acetate, polyoxyethylene sorbitan monolate, polyoxyl stearate 40, polyoxyethylene hardened castor
  • a surfactant such as oil, a stabilizer such as sodium quenate and sodium edetate, and a preservative such as benzalkonium chloride and paraben can be used as necessary. If the pH is within the range allowed for ophthalmic preparations, the range of 4-8 is preferred.
  • An eye ointment can be prepared using a widely used base such as white petrolatum or liquid paraffin.
  • Oral preparations such as tablets, capsules, granules, powders, etc. include bulking agents such as lactose, crystalline cellulose, starch, vegetable oil, lubricants such as magnesium stearate and talc, hydroxypropylcellulose, polybulurpyrrolidone, etc. 1J, carboxymethyl cellulose Calcium, low-substituted hydroxypropyl methylcellulose and other disintegrants, hydroxypropylmethylcellulose, macrogol, silicone resin, etc.
  • a film agent such as a latin film can be added as necessary to prepare the film.
  • the present invention also relates to a method for treating dry eye or a disease associated with dry eye, comprising administering an effective amount of the compound represented by the general formula (1) or a salt thereof to a patient.
  • the dose of the active ingredient can be appropriately selected depending on the symptom, age, dosage form, etc.
  • 0.0001-10% (wZv), preferably 0.001-3% (w / v) Do it one to several times.
  • 0.1 to 5000 mg per day usually preferably 1 to 1000 mg should be administered once or divided into several doses.
  • a dry eye model was prepared according to the method of Fujihara et al. (Invest. Ophthalmol. Vis. Sci 42 (1): 96-100 (2001)). After the dry eye model was prepared, corneal damage was scored according to the method of Murakami et al. (New Ophthalmology 21 (1): 87-90 (2004)), and the improvement rate of corneal damage after instillation of each statin compound was determined. Asked.
  • test compound (compounds A to H) was instilled (instillation amount: 5 ⁇ L / time) as follows.
  • a physiological phosphate buffer solution (PBS solution) of Compound A (0.02%) was instilled into both eyes 6 times a day for 14 days (4 eyes per group, 8 eyes).
  • Compound G ophthalmic group Compound G (0.002%) in PBS was applied to both eyelids 6 times a day for 14 days (4 animals per group, 8 eyes) 0
  • Improvement rate (%) ⁇ (control)-(this compound) ⁇ / disorder degree X 100
  • the concentration becomes 0.001% (, 0.1% (w / v), 0.3% (w / v), 1.0% (w / v), 3. 0% (Yes.
  • an ointment with a concentration of 1% (WZW) or 3% (wZw) can be prepared.
  • an ointment with a concentration of 1% (w / w) or 3% (w / w) can be prepared.
  • Each eye ointment can be prepared by using Compound C, Compound D, and Compounds F to H instead of Compound E.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une nouvelle utilisation d'un composé représenté par la formule générale (1) ou d’un sel de celui-ci. Selon cette invention, le composé représenté par la formule générale (1) ou un sel de celui-ci produit un excellent effet atténuant dans un test d’effet curatif de trouble de la cornée, basé sur un modèle d’oeil sec. Il est utile en tant qu’agent thérapeutique pour la sécheresse oculaire ou les pathologies associées à la sécheresse oculaire. Dans cette invention, le symbole A est alkylène inférieur ou un alkénylène inférieur ; le cycle X est un cycle non aromatique ou un hétérocycle aromatique azoté ; R1 est hydrogène ou alkyle inférieur et R2 est hydroxy, à condition que R1 puisse être condensé à R2 pour former un cycle lactone; R3 est hydrogène ou alkyle inférieur ; R4 est un alkyle inférieur facultativement substitué, cycloalkyle, aryle facultativement substitué, hydroxy ou un ester de celui-ci, alkoxy inférieur, carboxy ou un amide de celui, alkylamino inférieur ou un amide de celui; et m est un nombre entier compris entre 0 et 4, à condition que lorsque m est 2 ou plus, les R4 puissent être identiques ou différents.
PCT/JP2005/022913 2004-12-14 2005-12-14 Agent therapeutique pour la secheresse oculaire WO2006064825A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004361554 2004-12-14
JP2004-361554 2004-12-14

Publications (1)

Publication Number Publication Date
WO2006064825A1 true WO2006064825A1 (fr) 2006-06-22

Family

ID=36587881

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2005/022913 WO2006064825A1 (fr) 2004-12-14 2005-12-14 Agent therapeutique pour la secheresse oculaire

Country Status (1)

Country Link
WO (1) WO2006064825A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013113067A1 (fr) * 2012-02-02 2013-08-08 The University Of Sydney Améliorations dans la stabilité du film lacrymal

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000264847A (ja) * 1999-01-12 2000-09-26 Teruo Nishida 角膜障害治療剤
WO2002030425A1 (fr) * 2000-10-12 2002-04-18 Nissan Chemical Industries, Ltd. Medicaments pour la prevention ou le traitement de complications du diabete
JP2002205944A (ja) * 2000-11-08 2002-07-23 Santen Pharmaceut Co Ltd ファルネシル酢酸を有効成分とする角結膜疾患治療剤
JP2004149480A (ja) * 2002-10-31 2004-05-27 Saisentan Igaku Kenkyusho:Kk 経口又は経皮投与用の眼科疾患治療剤
JP2005145961A (ja) * 2003-10-24 2005-06-09 Santen Pharmaceut Co Ltd 角結膜障害の治療剤

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000264847A (ja) * 1999-01-12 2000-09-26 Teruo Nishida 角膜障害治療剤
WO2002030425A1 (fr) * 2000-10-12 2002-04-18 Nissan Chemical Industries, Ltd. Medicaments pour la prevention ou le traitement de complications du diabete
JP2002205944A (ja) * 2000-11-08 2002-07-23 Santen Pharmaceut Co Ltd ファルネシル酢酸を有効成分とする角結膜疾患治療剤
JP2004149480A (ja) * 2002-10-31 2004-05-27 Saisentan Igaku Kenkyusho:Kk 経口又は経皮投与用の眼科疾患治療剤
JP2005145961A (ja) * 2003-10-24 2005-06-09 Santen Pharmaceut Co Ltd 角結膜障害の治療剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PARK H.-J. ET AL.: "3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Interfere With Angiogenesis by Inhibiting the Geranylgeranylation of RhoA", CIRCUL. RES., vol. 91, no. 2, 26 July 2002 (2002-07-26), pages 143 - 150, XP002997966 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013113067A1 (fr) * 2012-02-02 2013-08-08 The University Of Sydney Améliorations dans la stabilité du film lacrymal
AU2013214693B2 (en) * 2012-02-02 2017-02-23 Kenneth Gek-Jin OOI Improvements in tear film stability
AU2017204257B2 (en) * 2012-02-02 2018-06-21 Kenneth Gek-Jin Ooi Improvements in tear film stability

Similar Documents

Publication Publication Date Title
US20090227602A1 (en) Compositions and treatments for inhibiting kinase and/or hmg-coa reductase
JP2008247898A (ja) トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤
US20040106654A1 (en) Inhibitors of copper-containing amine oxidases
CN100469776C (zh) 白内障和其它眼病发展的改善
US20150111919A1 (en) Compositions and methods for treating multiple sclerosis
KR20160113727A (ko) 트리아진 화합물 및 그의 의약 용도
JP2022534420A (ja) 眼のタンパク質凝集疾患を治療するための薬剤
US7772258B2 (en) Agent for treatment of allergic eye disease
WO2006064825A1 (fr) Agent therapeutique pour la secheresse oculaire
EP1325745B1 (fr) Medicaments pour la prevention ou le traitement de complications du diabete
WO2016068278A1 (fr) Inhibiteur de phacosclérose
WO2011149012A1 (fr) Agent prophylactique ou thérapeutique pour maladies de dénaturation rétinienne/choroïdienne comprenant un dérivé d'isoquinolinesulfonyle comme principe actif, procédé prophylactique ou thérapeutique pour maladies de dénaturation rétinienne/choroïdienne, et dérivé d'isoquinolinesulfonyle ou son sel pharmaceutiquement acceptable, et utilisation associée
JP2006193515A (ja) ドライアイ治療剤
BG63863B1 (bg) Използване на производни на сулфаминовата киселина, ацил сулфонамиди или сулфамоил карбамати за получаването на средство за понижаване на липопротеиновите нива
JP2005047909A (ja) ピペリジン誘導体を有効成分とする掻痒治療剤
TW201323425A (zh) 抗菌性咔啉化合物
JPH05503525A (ja) インドール誘導体、その製造及び使用
JP4922588B2 (ja) 角結膜障害治療剤
WO2006030753A1 (fr) Agent thérapeutique pour un trouble de type kératoconjonctivite
JP2004262812A (ja) 眼圧低下剤
JP2006104199A (ja) 角結膜障害治療剤
JP2010150243A (ja) ピリジン−３−カルバルデヒドｏ−（ピペリジン−１−イル−プロピル）−オキシム誘導体を有効成分として含有する網脈絡膜変性疾患の治療剤
US6028094A (en) Agent for prevention and suppression of dry coughing caused by angiotensin converting enzyme inhibitors
US20110201678A1 (en) Xanthenone-4-Acetic Acid Derivatives
US20040110825A1 (en) Method for treating sepsis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05816805

Country of ref document: EP

Kind code of ref document: A1